Oligon to Participate in the 9th Annual Fall Private Company Showcase hosted by Solebury Trout, BMO and Goodwin
SCOTTSDALE, Ariz.--(BUSINESS WIRE)--Oligon™ Inc., an emerging biotechnology company developing a novel class of multimodal RNA therapeutics for the treatment of cancer and other diseases, announced today that Dr. Spyro Mousses, CEO and Co-Founder, Andrew Matricaria, CFO, and James Silver, COO, will participate in the 9th Annual Solebury Trout Fall Private Company Showcase co-hosted with BMO and Goodwin on October 13, 2022 in New York, NY.
All three will host one-on-one investor meetings at the showcase, and Dr. Mousses will present a company overview during a 4:20 P.M. EDT session as part of the Track 2 schedule.
About Oligon
Oligon Inc. is developing a new class of multimodal RNA therapeutics that can simultaneously silence numerous disease targets with a single RNA molecule to improve outcomes and combat emerging drug resistance. Our proprietary SeekR™ platform is used to digitally engineer and rapidly produce self-delivering therapeutics which target specific tissues with unprecedented precision and accuracy. We are focused on building a pipeline of products in oncology, yet our multimodal RNA platform can be harnessed to transform outcomes for any complex multigenic disease. To learn more about Oligon, please visit www.oligon.com.
Contacts
Katy Marhenke
VP, Business Administration
kmarhenke@oligon.com
Editor Details
-
Company:
- Businesswire
